News & Media

This EOM Pharmaceuticals website may contain information, news, and/or press releases, the content of which is accurate or current only as of the date of the particular information, news, press release, or posting. EOM does not update press releases once they have been made public.

Media Kit

News Highlights

Press Release

EOM PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN R1: RESCUE PHASE 1/2A OPEN-LABEL TRIAL EVALUATING EOM613 IN HOSPITALIZED COVID-19 PATIENTS WITH SEVERE SYMPTOMS IN BRAZIL

August 24, 2021

MONTVALE, N.J. – August 24, 2021 — EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, announced the first patients have been dosed in R1: RESCUE, a proof-of-concept Phase 1/2a open-label multicenter clinical study in Brazil to evaluate safety, tolerability, and preliminary efficacy of EOM613 in hospitalized COVID-19 infected patients with severe symptoms.

READ MORE »

Press Release

EOM PHARMACEUTICALS APPOINTS DRUG DEVELOPMENT VETERAN FRANK L. DOUGLAS, Ph.D., M.D., SCIENTIFIC ADVISOR

July 22, 2021

MONTVALE, N.J. – July 20, 2021 — EOM Pharmaceuticals, Inc., a privately-held, clinical-stage company, today announced the appointment of Frank L. Douglas, Ph.D., M.D., to Scientific Advisor. Dr. Douglas will be responsible for guiding the company’s clinical and scientific strategies for EOM lead candidate EOM613, as well as forming and chairing the EOM Scientific Advisory […]

READ MORE »

Press Releases

August 24, 2021

EOM PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN R1: RESCUE PHASE 1/2A OPEN-LABEL TRIAL EVALUATING EOM613 IN HOSPITALIZED COVID-19 PATIENTS WITH SEVERE SYMPTOMS IN BRAZIL

DOWNLOAD

July 22, 2021

EOM PHARMACEUTICALS APPOINTS DRUG DEVELOPMENT VETERAN FRANK L. DOUGLAS, Ph.D., M.D., SCIENTIFIC ADVISOR

DOWNLOAD